Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial | Stroke and Vascular Neurology

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest Content

Current issue

Archive

For authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Original research

Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Meng X, Wang A, Zhang G, et al

Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial

Stroke and Vascular Neurology 2021;6:doi: 10.1136/svn-2021-000874